Elaine M Leslie

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8054927/publications.pdf

Version: 2024-02-01

50 papers	4,538 citations	172457 29 h-index	223800 46 g-index
50 all docs	50 docs citations	50 times ranked	4551 citing authors

#	Article	IF	Citations
1	Transporters and Toxicity: Insights From the International Transporter Consortium Workshop 4. Clinical Pharmacology and Therapeutics, 2022, 112, 527-539.	4.7	4
2	Determining site occupancy of acetaminophen covalent binding to target proteins in vitro. Analytical Science Advances, 2021, 2, 263-271.	2.8	0
3	Selenide stimulates the biliary excretion of arsenic in human HepaRG cells. FASEB Journal, 2021, 35, .	0.5	0
4	Biliary excretion of arsenic by human HepaRG cells is stimulated by selenide and mediated by the multidrug resistance protein 2 (MRP2/ABCC2). Biochemical Pharmacology, 2021, 193, 114799.	4.4	2
5	Efflux transporters in anti-cancer drug resistance: Molecular and functional identification and characterization of multidrug resistance proteins (MRPs/ABCCs). , 2020, , 31-65.		1
6	Human red blood cell uptake and sequestration of arsenite and selenite: Evidence of seleno-bis(S-glutathionyl) arsinium ion formation in human cells. Biochemical Pharmacology, 2020, 180, 114141.	4.4	7
7	Studies of selenium and arsenic mutual protection in human HepG2 cells. Chemico-Biological Interactions, 2020, 327, 109162.	4.0	7
8	The novel p.Ser263Phe mutation in the human highâ€affinity choline transporter 1 (CHT1/ SLC5A7) causes a lethal form of fetal akinesia syndrome. Human Mutation, 2019, 40, 1676-1683.	2.5	14
9	Redox metabolism of ingested arsenic: Integrated activities of microbiome and host on toxicological outcomes. Current Opinion in Toxicology, 2019, 13, 90-98.	5.0	11
10	Metabolism of a Phenylarsenical in Human Hepatic Cells and Identification of a New Arsenic Metabolite. Environmental Science & Technology, 2018, 52, 1386-1392.	10.0	17
11	Multidrug Resistance Protein 1 (MRP1/ABCC1)-Mediated Cellular Protection and Transport of Methylated Arsenic Metabolites Differs between Human Cell Lines. Drug Metabolism and Disposition, 2018, 46, 1096-1105.	3.3	12
12	Absolute quantitation of acetaminophenâ€modified human serum albumin in acute liver failure patients by liquid chromatography/tandem mass spectrometry. Rapid Communications in Mass Spectrometry, 2018, 32, 1573-1582.	1.5	10
13	Multidrug Resistance Protein 4 (MRP4/ABCC4) Protects Cells from the Toxic Effects of Halobenzoquinones. Chemical Research in Toxicology, 2017, 30, 1815-1822.	3.3	16
14	Arsenic Triglutathione [As(GS)₃] Transport by Multidrug Resistance Protein 1 (MRP1/ABCC1) Is Selectively Modified by Phosphorylation of Tyr920/Ser921 and Glycosylation of Asn19/Asn23. Molecular Pharmacology, 2016, 90, 127-139.	2.3	21
15	Polymorphic variants of MRP4/ABCC4 differentially modulate the transport of methylated arsenic metabolites and physiological organic anions. Biochemical Pharmacology, 2016, 120, 72-82.	4.4	32
16	Cellular arsenic transport pathways in mammals. Journal of Environmental Sciences, 2016, 49, 38-58.	6.1	71
17	Accumulation and Transport of Roxarsone, Arsenobetaine, and Inorganic Arsenic Using the Human Immortalized Caco-2 Cell Line. Journal of Agricultural and Food Chemistry, 2016, 64, 8902-8908.	5.2	14
18	Detection of Ophthalmic Acid in Serum from Acetaminophen-Induced Acute Liver Failure Patients Is More Frequent in Non-Survivors. PLoS ONE, 2015, 10, e0139299.	2.5	16

#	Article	IF	Citations
19	Characterization of Arsenic Hepatobiliary Transport Using Sandwich-Cultured Human Hepatocytes. Toxicological Sciences, 2015, 145, 307-320.	3.1	20
20	A Novel Pathway for Arsenic Elimination: Human Multidrug Resistance Protein 4 (MRP4/ABCC4) Mediates Cellular Export of Dimethylarsinic Acid (DMA^V) and the Diglutathione Conjugate of Monomethylarsonous Acid (MMA^{III}). Molecular Pharmacology, 2014, 86, 168-179.	2.3	45
21	Character and Temporal Evolution of Apoptosis in Acetaminophen-Induced Acute Liver Failure*. Critical Care Medicine, 2013, 41, 2543-2550.	0.9	37
22	Arsenicâ€“glutathione conjugate transport by the human multidrug resistance proteins (MRPs/ABCCs). Journal of Inorganic Biochemistry, 2012, 108, 141-149.	3.5	119
23	Comparative Toxicity of Arsenic Metabolites in Human Bladder Cancer EJ-1 Cells. Chemical Research in Toxicology, 2011, 24, 1586-1596.	3.3	129
24	Monomethylarsenic Diglutathione Transport by the Human Multidrug Resistance Protein 1 (MRP1/ABCC1). Drug Metabolism and Disposition, 2011, 39, 2298-2304.	3.3	38
25	Glutathione Transferase P1 Interacts Strongly with the Inner Leaflet of the Plasma Membrane. Drug Metabolism and Disposition, 2011, 39, 1122-1126.	3.3	8
26	Regulation of Arsenic Triglutathione [As(GS) 3] Transport by the Human Multidrug Resistance Protein 1 (MRP1/ABCC1) Through Postâ€translational Modification. FASEB Journal, 2011, 25, lb502.	0.5	0
27	Selenium-dependent and -independent transport of arsenic by the human multidrug resistance protein 2 (MRP2/ABCC2): implications for the mutual detoxification of arsenic and selenium. Carcinogenesis, 2010, 31, 1450-1455.	2.8	60
28	Use of Tc-99m Mebrofenin as a Clinical Probe to Assess Altered Hepatobiliary Transport: Integration of In Vitro, Pharmacokinetic Modeling, and Simulation Studies. Pharmaceutical Research, 2008, 25, 1851-1860.	3.5	86
29	Modulation of trabectedin (ET-743) hepatobiliary disposition by multidrug resistance-associated proteins (Mrps) may prevent hepatotoxicity. Toxicology and Applied Pharmacology, 2008, 228, 17-23.	2.8	27
30	Biotransformation and transport of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in bile duct-cannulated wild-type and Mrp2/Abcc2-deficient (TR) Wistar rats. Carcinogenesis, 2007, 28, 2650-2656.	2.8	15
31	Differential Inhibition of Rat and Human Na+-Dependent Taurocholate Cotransporting Polypeptide (NTCP/SLC10A1)by Bosentan: A Mechanism for Species Differences in Hepatotoxicity. Journal of Pharmacology and Experimental Therapeutics, 2007, 321, 1170-1178.	2.5	119
32	In Vitroâ€“In Vivo Correlation of Hepatobiliary Drug Clearance in Humans. Clinical Pharmacology and Therapeutics, 2007, 81, 406-413.	4.7	117
33	Use of Sandwich-Cultured Hepatocytes To Evaluate Impaired Bile Acid Transport as a Mechanism of Drug-Induced Hepatotoxicity. Molecular Pharmaceutics, 2007, 4, 911-918.	4.6	80
34	Methods To Evaluate Biliary Excretion of Drugs in Humans:â€‰ An Updated Review. Molecular Pharmaceutics, 2006, 3, 198-211.	4.6	136
35	Acquired Cadmium Resistance in Metallothionein-I/II(â€“/â€“) Knockout Cells: Role of the T-Type Calcium Channel CacnÎ±1Gin Cadmium Uptake. Molecular Pharmacology, 2006, 69, 629-639.	2.3	47
36	Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicology and Applied Pharmacology, 2005, 204, 216-237.	2.8	1,222

#	Article	IF	Citations
37	Arsenic Transport by the Human Multidrug Resistance Protein 1 (MRP1/ABCC1). Journal of Biological Chemistry, 2004, 279, 32700-32708.	3.4	227
38	Identification of Proline Residues in the Core Cytoplasmic and Transmembrane Regions of Multidrug Resistance Protein 1 (MRP1/ABCC1) Important for Transport Function, Substrate Specificity, and Nucleotide Interactions. Journal of Biological Chemistry, 2004, 279, 12325-12336.	3.4	63
39	Nitric oxide prodrugs and metallochemotherapeutics: JS-K and CB-3-100 enhance arsenic and cisplatin cytolethality by increasing cellular accumulation. Molecular Cancer Therapeutics, 2004, 3, 709-14.	4.1	47
40	CFTR directly mediates nucleotide-regulated glutathione flux. EMBO Journal, 2003, 22, 1981-1989.	7.8	193
41	Functional and Structural Consequences of Cysteine Substitutions in the NH2Proximal Region of the Human Multidrug Resistance Protein 1 (MRP1/ABCC1)â€. Biochemistry, 2003, 42, 5214-5224.	2.5	73
42	Structural Requirements for Functional Interaction of Glutathione Tripeptide Analogs with the Human Multidrug Resistance Protein 1 (MRP1). Journal of Pharmacology and Experimental Therapeutics, 2003, 304, 643-653.	2.5	50
43	Bioflavonoid Stimulation of Glutathione Transport by the 190-kDa Multidrug Resistance Protein 1 (MRP1). Drug Metabolism and Disposition, 2003, 31, 11-15.	3.3	125
44	A naturally occurring mutation in MRP1 results in a selective decrease in organic anion transport and in increased doxorubicin resistance. Pharmacogenetics and Genomics, 2002, 12, 321-330.	5.7	112
45	Toxicological relevance of the multidrug resistance protein 1, MRP1 (ABCC1) and related transporters. Toxicology, 2001, 167, 3-23.	4.2	364
46	Transport of the Î²-O-Glucuronide Conjugate of the Tobacco-specific Carcinogen 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) by the Multidrug Resistance Protein 1 (MRP1). Journal of Biological Chemistry, 2001, 276, 27846-27854.	3.4	147
47	Modulation of Multidrug Resistance Protein 1 (MRP1/ABCC1) Transport and ATPase Activities by Interaction with Dietary Flavonoids. Molecular Pharmacology, 2001, 59, 1171-1180.	2.3	228
48	Monoclonal Antibodies That Inhibit the Transport Function of the 190-kDa Multidrug Resistance Protein, MRP. Journal of Biological Chemistry, 1999, 274, 15420-15426.	3.4	71
49	ATPase activity of purified and reconstituted multidrug resistance protein MRP1 from drug-selected H69AR cells. Biochimica Et Biophysica Acta - Biomembranes, 1999, 1461, 69-82.	2.6	89
50	Membrane Topology of the Multidrug Resistance Protein (MRP). Journal of Biological Chemistry, 1997, 272, 23623-23630.	3.4	189